Navigation Links
Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca
Date:9/24/2007

MONTEREY, Calif., Sept. 24 /PRNewswire/ -- Today, the rights to Verus Pharmaceuticals' pediatric asthma development programs that utilize PARI's eFlow electronic nebulizer for aerosol delivery were acquired by AstraZeneca. Following Gilead Sciences' acquisition of Corus Pharma in August 2006, this is the second major pharmaceutical acquisition where a licensed eFlow is featured prominently in the development pipeline.

Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aerosol delivery device) for use with both products, and other intellectual property and related assets from Verus.

This is the second acquisition by a large pharmaceutical company where purchases have included the licensing of PARI's eFlow in the development program. In August 2006, Gilead Sciences acquired Corus Pharma for $365 million. In December 2006, Gilead Sciences released positive preliminary results of their Phase III trial on AIR-CF2, a potential treatment for cystic fibrosis patients that have pulmonary Pseudomonas aeruginosa. These positive preliminary results were the first Phase III clinical trial results highlighting the optimization of drug to device and device to drug with PARI's eFlow, an advanced electronic nebulizer.

About eFlow

eFlow uses a vibrating, perforated membrane that enables extremely efficient aerosolization of liquid medications. Compared to other nebulizer systems, eFlow can produce aerosols with a very high density of active drug, a precisely defined droplet size, and a high proportion of respirable droplets delivered in the shortest possible amount of time. Combined with its silent mode of operation, small size (it fits in the palm of your hand), light weight, and battery use, eFlow helps reduce the burden of taking daily-inhaled treatments.

Due to its efficiency, eFlow is licensed to pharmaceutical companies during drug development and for later commercialization so that drug and device are optimized together for the final product. This customization is currently being utilized in the development of new and improved treatments for cystic fibrosis, asthma, and chronic obstructive pulmonary disease (COPD).

About PARI Pharma

PARI Pharma develops aerosol delivery devices and inhaled therapies. Based on PARI's 100-year history working with aerosols, PARI Pharma specializes in treatments for pulmonary and nasal administration optimized to advanced delivery platforms, such as eFlow.

Focusing on comprehensive inhalation therapy development, including optimized nebulizer formulations, analytics, and aerosol characterization, PARI Pharma has several clinical development programs ongoing, either partnered or proprietary. PARI Pharma, a PARI Medical Holding company, is located in Munich, Germany, with a major presence in the United States. Online at http://www.paripharma.com


'/>"/>
SOURCE PARI Pharma
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. High-throughput gene expression analysis to screen for anti-asthma drugs
2. Bio-Plex Cytokine Immunoassays and ELISA: Comparison of Two Methodologies in Testing Samples From Asthmatic and Healthy Children, Rev A
3. Are guest worker programs causing backlash amid IT downsizing?
4. FDA programs encourage and expedite drug development and approval
5. SecurePipe acquires mailMax programs
6. British come to Madison; UW starts stem-cell programs
7. Stem-cell study grows too big for one department; UW builds collaborative programs
8. Inacom targets diversity programs as Milwaukee expansion drives growth
9. Interview: New commerce secretary wants to keep momentum on jobs and business programs
10. Experts share advice for Wisconsin entrepreneur programs
11. An analysis of Wisconsins new venture capital and early stage finance programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... City, Missouri (PRWEB) , ... May 27, 2016 , ... ... Development Manager, Turf and Ornamental Products. , In his 15-year career with PBI-Gordon, Dave ... Herbicide Product Manager, where he was integral in the development and launch of many ...
(Date:5/26/2016)... LAKE LINDEN, Mich. , May 26, 2016 /PRNewswire/ ... of Des Moines, Iowa is ... blooms in Lake Erie and ... nutrients is key to preventing this widespread issue. ... Michigan,s Upper Peninsula, developed a new, ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several promising ... at the City of Knowledge in Panama, a 6 year-old Duchenne’s muscular ... US earlier this year following FDA approval of a second application for a ...
(Date:5/25/2016)... Bangkok, Thailand (PRWEB) , ... May 25, 2016 ... ... the participation of a Thai delegation at BIO 2016 in San Francisco. Located ... private sector will be available to answer questions and discuss the Thai biotechnology ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... "Global Gait Biometrics Market 2016-2020,"  report to their ... ) , ,The global gait biometrics market ... 13.98% during the period 2016-2020. Gait ... which can be used to compute factors that ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/18/2016)... --> --> Competitive Landscape ... Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which is ... & security companies in the border security market and ...
Breaking Biology News(10 mins):